NCT03105375 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

October 12, 2017

Study Completion Date

October 12, 2017

Conditions

Healthy Volunteers

Interventions

DRUG

Single ascending dose of X842

Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.

DRUG

Multiple ascending dose of X842

Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.

DRUG

Losec

Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.

Trial Locations (1)

75237

Clinical Trial Consultants, Uppsala